Sen. John Boozman Acquires Albemarle Corporation (NYSE:ALB) Stock

Senator John Boozman (Republican-Arkansas) recently bought shares of Albemarle Corporation (NYSE:ALB). In a filing disclosed on June 16th, the Senator disclosed that they had bought between $1,001 and $15,000 in Albemarle stock on May 15th.

Senator John Boozman also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BondBloxx Bloomberg Two Year Target Duration US Treasury ETF (NYSEARCA:XTWO) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of BondBloxx Bloomberg Five Year Target Duration US Treasury ETF (NYSEARCA:XFIV) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of Goldman Sachs Access Investment Grade Corporate Bond ETF (NYSEARCA:GIGB) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of Goldman Sachs Access Treasury 0-1 Year ETF (NYSEARCA:GBIL) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of iShares Agency Bond ETF (NYSEARCA:AGZ) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of iShares MBS ETF (NASDAQ:MBB) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of iShares CMBS ETF (NYSEARCA:CMBS) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of iShares 10-20 Year Treasury Bond ETF (NYSEARCA:TLH) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of iShares 7-10 Year Treasury Bond ETF (NASDAQ:IEF) on 5/27/2026.
• Purchased $1,001 – $15,000 in shares of Janus Henderson Mortgage-Backed Securities ETF (NYSEARCA:JMBS) on 5/27/2026.

Albemarle Stock Down 4.2%

Shares of ALB stock traded down $6.16 during trading hours on Thursday, reaching $141.68. The company had a trading volume of 1,542,320 shares, compared to its average volume of 2,500,558. The company has a market cap of $16.71 billion, a price-to-earnings ratio of -41.55, a price-to-earnings-growth ratio of 0.76 and a beta of 1.30. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.07 and a quick ratio of 1.21. Albemarle Corporation has a 12 month low of $60.64 and a 12 month high of $221.00. The business has a fifty day simple moving average of $178.65 and a 200-day simple moving average of $169.24.

Albemarle (NYSE:ALB) last announced its quarterly earnings results on Wednesday, May 6th. The specialty chemicals company reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $1.71. Albemarle had a positive return on equity of 5.22% and a negative net margin of 5.00%.The business had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.34 billion. During the same quarter in the prior year, the company posted ($0.18) earnings per share. Albemarle’s revenue was up 32.7% compared to the same quarter last year. On average, research analysts expect that Albemarle Corporation will post 12.39 earnings per share for the current fiscal year.

Albemarle Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Friday, June 12th will be issued a $0.405 dividend. This represents a $1.62 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Friday, June 12th. Albemarle’s dividend payout ratio (DPR) is currently -47.51%.

Insiders Place Their Bets

In other news, CEO J Kent Masters sold 16,393 shares of Albemarle stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $183.72, for a total value of $3,011,721.96. Following the completion of the transaction, the chief executive officer owned 87,519 shares in the company, valued at $16,078,990.68. This trade represents a 15.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.42% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Albemarle

Hedge funds have recently modified their holdings of the stock. Sapient Capital LLC purchased a new stake in Albemarle in the first quarter worth $484,000. Empowered Funds LLC grew its stake in shares of Albemarle by 1,455.8% during the 1st quarter. Empowered Funds LLC now owns 32,982 shares of the specialty chemicals company’s stock worth $5,921,000 after acquiring an additional 30,862 shares during the period. Dakota Community Bank & Trust NA purchased a new stake in Albemarle in the 1st quarter worth about $54,000. Parallel Advisors LLC increased its holdings in Albemarle by 4.9% in the 1st quarter. Parallel Advisors LLC now owns 2,588 shares of the specialty chemicals company’s stock worth $465,000 after acquiring an additional 120 shares during the last quarter. Finally, NewEdge Advisors LLC raised its stake in Albemarle by 9.3% in the 1st quarter. NewEdge Advisors LLC now owns 8,679 shares of the specialty chemicals company’s stock valued at $1,558,000 after acquiring an additional 740 shares during the period. Institutional investors own 92.87% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on ALB. HSBC boosted their price target on shares of Albemarle from $200.00 to $220.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Oppenheimer boosted their target price on Albemarle from $216.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, April 13th. Berenberg Bank increased their price target on Albemarle from $153.00 to $192.00 and gave the company a “hold” rating in a research report on Tuesday, June 2nd. Jefferies Financial Group lifted their price target on Albemarle from $230.00 to $244.00 in a report on Monday, May 11th. Finally, Mizuho boosted their price objective on Albemarle from $185.00 to $205.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $202.54.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

About Albemarle

Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company’s bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.

Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world’s foremost chemical producers.